» Articles » PMID: 36944981

GLUT1-DS Italian Registry: Past, Present, and Future: a Useful Tool for Rare Disorders

Abstract

Background: GLUT1 deficiency syndrome is a rare, genetically determined neurological disorder for which Ketogenic Dietary Treatment represents the gold standard and lifelong treatment. Patient registries are powerful tools providing insights and real-world data on rare diseases.

Objective: To describe the implementation of a national web-based registry for GLUT1-DS.

Methods: This is a retrospective and prospective, multicenter, observational registry developed in collaboration with the Italian GLUT1-DS association and based on an innovative, flexible and configurable cloud computing technology platform, structured according to the most rigorous requirements for the management of patient's sensitive data. The Glut1 Registry collects baseline and follow-up data on the patient's demographics, history, symptoms, genotype, clinical, and instrumental evaluations and therapies.

Results: Five Centers in Italy joined the registry, and two more Centers are currently joining. In the first two years of running, data from 67 patients (40 females and 27 males) have been collected. Age at symptom onset was within the first year of life in most (40, 60%) patients. The diagnosis was formulated in infancy in almost half of the cases (34, 51%). Symptoms at onset were mainly paroxysmal (mostly epileptic seizure and paroxysmal ocular movement disorder) or mixed paroxysmal and fixed symptoms (mostly psychomotor delay). Most patients (53, 79%) are currently under Ketogenic dietary treatments.

Conclusions: We describe the principles behind the design, development, and deployment of the web-based nationwide GLUT1-DS registry. It represents a stepping stone towards a more comprehensive understanding of the disease from onset to adulthood. It also represents a virtuous model from a technical, legal, and organizational point of view, thus representing a possible paradigmatic example for other rare disease registry implementation.

Citing Articles

Dietary management and access to treatment for patients with glucose deficiency syndrome type 1: an overview review with focus on the European regulatory framework.

Zovi A, Cifani C, Confalonieri C, Lasala R, Sabbatucci M, Vitiello A Eur J Clin Nutr. 2024; 78(12):1058-1063.

PMID: 39127841 DOI: 10.1038/s41430-024-01490-0.


GLUT-1DS resistant to ketogenic diet: from clinical feature to in silico analysis. An exemplificative case report with a literature review.

Falsaperla R, Sortino V, Vitaliti G, Privitera G, Ruggieri M, Fusto G Neurogenetics. 2024; 25(2):69-78.

PMID: 38190079 DOI: 10.1007/s10048-023-00742-8.

References
1.
Ali S, Bryce J, Kodra Y, Taruscio D, Persani L, Ahmed S . The Quality Evaluation of Rare Disease Registries-An Assessment of the Essential Features of a Disease Registry. Int J Environ Res Public Health. 2021; 18(22). PMC: 8620980. DOI: 10.3390/ijerph182211968. View

2.
Klepper J, Leiendecker B . GLUT1 deficiency syndrome--2007 update. Dev Med Child Neurol. 2007; 49(9):707-16. DOI: 10.1111/j.1469-8749.2007.00707.x. View

3.
Klepper J, Akman C, Armeno M, Auvin S, Cervenka M, Cross H . Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open. 2020; 5(3):354-365. PMC: 7469861. DOI: 10.1002/epi4.12414. View

4.
Hao J, Kelly D, Su J, Pascual J . Clinical Aspects of Glucose Transporter Type 1 Deficiency: Information From a Global Registry. JAMA Neurol. 2017; 74(6):727-732. PMC: 5822202. DOI: 10.1001/jamaneurol.2017.0298. View

5.
Kass H, Winesett S, Bessone S, Turner Z, Kossoff E . Use of dietary therapies amongst patients with GLUT1 deficiency syndrome. Seizure. 2016; 35:83-7. DOI: 10.1016/j.seizure.2016.01.011. View